Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120067 · ClinicalTrials.gov registry record · NA
Intensive Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT01120067: Completed NA study, sponsored by VA Office of Research and Development.
NCT01120067 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01120067, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is investigating the efficacy of an intensive (3 week) integrated treatment for Veterans with both pain and PTSD.
Primary Outcome
McGill Pain Questionnaire (MPQ; Melzack, 1975): is a self-report questionnaire consisting of 102 words separated into three major classes; the sensory, affective, and evaluative aspects of pain. Respondents are asked to circle the word that best describes their pain. The stability, reliability, and validity of the MPQ have been established (Reading, Everitt, \& Sledmere, 1982). The MPQ total score ranges from 0 to 78 with higher values indicating more significant pain.
Interventions
- BEHAVIORAL Treatment as Usual
- BEHAVIORAL Intensive Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-08-01 |
| Est. Completion | 2016-12-29 |
| Phase | NA |
What the finished NCT01120067 record still lists
NCT01120067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Treatment as Usual is the first listed.
NCT01120067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01120067 about?
NCT01120067 is a clinical study titled "Intensive Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)". This study is investigating the efficacy of an intensive (3 week) integrated treatment for Veterans with both pain and PTSD.
What is the current status of trial NCT01120067?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2010-08-01. Estimated completion is 2016-12-29.
What interventions are being tested in trial NCT01120067?
The interventions under investigation include: Treatment as Usual (BEHAVIORAL), Intensive Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT01120067?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01120067's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI